| Literature DB >> 33251090 |
Ricardo Taipe1, Mardonio Euscatigue2, Fernando Valdivia2, Brenner Belloso3, Irene Huaroto4.
Abstract
OBJECTIVE: To describe the form of severe clinical presentation of SARS-COV-2 infection in the early phase, also the timely treatment of COVID-19 pneumonia in postoperative pulmonary lobectomy.Entities:
Keywords: AARB, Acid alcohol resistant bacillus; C-RP, C-reactive protein; COVID-19; COVID-19, Coronavirus disease-19; FiO2, Inspired fraction oxygen; IgM/IgG, Immunoglobulins M and G; LDH, Lactate dehydrogenase; Lobectomy; Lung abscess; PaO2, Oxygen blood pressure; RT PCR, Real time polymerase chain reaction; SARS-COV-2; SARS-COV-2, Severe acute respiratory syndrome coronavirus 2; SatO2, Oxyhemoglobin saturation; WHO, World Health Organization
Year: 2020 PMID: 33251090 PMCID: PMC7678424 DOI: 10.1016/j.ijscr.2020.11.020
Source DB: PubMed Journal: Int J Surg Case Rep ISSN: 2210-2612
Fig. 1Preoperative chest tomography shows a cystic image with heterogeneous content and a thickened wall that compromises the lower left lobe.
Fig. 2Preoperative chest tomography showing the lower third of the lung showing signs of hepatization.
Fig. 3Postlobectomy surgical specimen shows hepatized left lower lobe.
Fig. 4Resected left lower lobe shows lung abscess with signs of vascular thrombosis and edematous lung parenchyma that compromises its entire extension.
Fig. 5Chest X-ray on the second postoperative day shows left lung reexpansion, no signs of pneumonia in the lung parenchyma, chest drainage directed towards the lung dome.
Fig. 6Tomography of the chest on the fourth postoperative day shows a ground glass pattern, compatible with SARS-COV-2 pneumonia. Note the involvement of both lungs, but predominantly the right lung.
Fig. 7Chest tomography on the fourth postoperative day shows a “crazy paving” pattern of SARS-COV-2, especially of the right lung. Note the re-expansion of the left upper lobe after surgery.
Evolution of vital functions in the perioperative period.
| V. F. | PO1 | PO3 | PO4 | PO5 | PO7 | PO8 | PO9 | PO10 | PO13 | PO14 | PO15 | PO16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T (°C) | 38,5 | 39 | 38,2 | 39 | 38 | 38 | 37,5 | 36,8 | 37 | 36 | 36,5 | 36 |
| HR (bpm) | 95 | 118 | 116 | 92 | 100 | 105 | 94 | 90 | 92 | 84 | 86 | 80 |
| SatO2 (%) | 97 | 93 | 90 | 86 | 90 | 88 | 90 | 93 | 94 | 96 | 97 | 98 |
V. F.: Vital functions, T: Temperature, HR: Heart rate, SatO2: Oximetry, PO: postoperative day, bpm: beats per minute, °C: degrees Celsius.
Evolution of arterial gases in the perioperative period.
| AGA | V. N. | Postoperative 4 | Postoperative 7 | Postoperative 10 | Postoperative 14 |
|---|---|---|---|---|---|
| pH | 7.37–7.45 | 7,2 | 7,1 | 7.4 | 7.5 |
| pO2 | 71–104 | 60 | 54 | 56 | 62 |
| pCO2 | 35–46 | 50 | 51 | 34 | 36 |
| HCO3 | 21–26 | 20 | 18 | 23 | 29 |
| Sat O2 | 94–100% | 91 | 88 | 90 | 93 |
| FIO2 | 0,4 | 0,5 | 0,6 | 0.32 |
AAG: Analysis of arterial gases, N. V.: Normal values.
Results of acute phase reactants and requested tests.
| Exam | Preoperative | Posoperative 4 | Postoperative 7 | Postoperative 10 | Postoperative 14 |
|---|---|---|---|---|---|
| Red blood cells | 4430000 | 3810000 | 3410000 | 3740000 | 3520000 |
| Leukocytes | 9890 | 19600 | 23200 | 12850 | 10800 |
| Segmented | 89% | 85 | 89 | 80 | 80 |
| Stocked | 0% | 1 | 2 | 0 | 0 |
| Lymphocytes | 20% | 6% | 3% | 4% | 18% |
| Platelets | 309000 | ||||
| Hemoglobin | 13.6 | 13 | 12,8 | 11,6 | 10.6 |
| Creatinine | 0,35 | 0,34 | 0,34 | 0.26 | |
| Ferritin | 1350 | 3809 | 1715 | 780 | |
| DHL | 1050 | 1143 | 1067 | 910 | |
| Proteina C | 90 | 144 | 63 | 23 | |
| D-dimer | 17 | 17 | 8 |
DHL: Lactate dehydrogenase, N.V.: Normal values.
Figs. 8 and 9H and E (20×) Concentric vascular hypertrophy of the middle muscular layer (left side), Microabscess zone (right side).
Figs. 10 and 11HyE (10×, 40×) Bronchiectasis with mixed inflammatory exudate and macrophages; partial destruction of the epithelium.
Figs. 12 and 13H and E (20×, 40×) Interstitium with the presence of lymphohistioplasmacytic inflammatory infiltrate and fibroblastic proliferation.
Figs. 14 and 15(20×, 40×) Fibrin deposits, mixed inflammatory infiltrate and intraalveolar multinucleated giant cells.